Skip to main content
. 2011 Nov 16;14(2):215–221. doi: 10.1093/neuonc/nor198

Fig. 1.

Fig. 1.

Kaplan–Meier plots stratified by prior bevacizumab use relative to time to progression (TTP); (A) and overall survival (OS); (B). Prior bevacizumab treatment is associated with a reduced TTP, but the difference was not statistically significant (P = .0627). Prior bevacizumab is associated with a significantly reduced OS (P = .0017).